Brief: Revive Therapeutics Provides Update From FDA Meeting For Long Covid Diagnostic Product
10/06/2024 12:31
June 10 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE FROM FDA MEETING FOR
LONG
COVID DIAGNOSTIC PRODUCT
* REVIVE THERAPEUTICS LTD: FDA HAS DETERMINED THAT PRODUCT
SHOULD
FOLLOW DE NOVO REGULATORY PATHWAY
* REVIVE THERAPEUTICS LTD: WOULD BE REQUIRED TO CONDUCT A
CLINICAL
STUDY FOR DE NOVO SUBMISSION FOR POSSIBLE APPROVAL
Source text for Eikon: ID:nGNXbD3Ywf
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure